The vaccine proves safe in a small sample of human subjects, opening the way for the next phase of testing
A new colorectal cancer vaccine showed positive results in the phase 1 clinical trial to demonstrate that the approach is safe. The patients treated had no signs of serious adverse events and samples of their blood contained markers of immune activation — an early indication that the vaccine could activate immune cells to fight colorectal tumors and metastases. Further tests to determine if the vaccine is effective at slowing tumor growth are forthcoming.
The results were published in the Journal for ImmunoTherapy of Cancer.
Colon cancer, especially in younger people, is on the rise and is currently the second highest cause of cancer deaths in the US and worldwide. Surgery can cure the disease in many patients, but prognosis is poor for those with recurrence of their disease. If it proves effective in larger-scale trials the vaccine, developed by researchers at Jefferson (Philadelphia University + Thomas Jefferson University), could train the patient’s immune system to attack the colon cancer that had already spread before the surgery.
“There is an urgent need to understand what fuels colorectal cancer growth, and to harness that knowledge for developing novel therapies. This pivotal study provides some of the first evidence that it may be possible to safely direct a patient’s own immune system to seek and destroy this cancer type. This is a true milestone– made possible through the scientists and clinicians in our colorectal cancer team working in synchrony”, said Karen E. Knudsen, PhD, EVP of Oncology Services and Director of the Sidney Kimmel Cancer Center — Jefferson Health.
In earlier preclinical work in mice, Jefferson researchers demonstrated how the design of their vaccine worked. Tumor vaccines have historically been developed against a sort of molecular sign-post for cancer. Because they come from normal cells, cancer cells share nearly all of the same molecules, making it difficult for the immune system to differentiate normal from cancerous. Tumor antigens are molecules that the immune system can recognize as different from normal. In colorectal cancer, one such molecule called GUCY2C, was identified by Scott Waldman, MD, PhD, the Samuel M.V. Hamilton Professor and Director of the Gastrointestinal Cancer Program of the Sidney Kimmel Cancer Center — Jefferson Health.
The vaccine developed by first author, Adam Snook, PhD, Assistant Professor in the Department of Pharmacology and Experimental Therapeutics, Dr. Waldman and others, works by activating the immune system against the GUCY2C molecule. By joining the GUCY2C molecule with a molecule that boosts the immune reaction called PADRE, and loading it into an adenovirus vector, the researchers engineered a vaccine that could specifically target the colon cancer.
The current clinical trial enrolled 10 patients with stage I or II colon cancer. Patients were given one dose and came back for blood draws 30, 90, 180 days after immunization. Patients experienced some discomfort at the injection site, but reported no serious side effects of the vaccine. The blood samples showed activation of “killer T cells,” the immune cell type the researchers had expected. These killer T cells are responsible for finding and killing colon cancer cells that are responsible for causing the cancer to come back.
“We are preparing for a phase II study that will begin recruiting patients this fall,” says Dr. Snook. “We used lessons learned in the first study to modify the vaccine to hopefully make it even more effective.”
Since starting the trial, the researchers found that cancers other than colorectal cancer also express GUCY2C, including gastric, esophageal and pancreatic cancer. These are actually among the deadliest cancers. In fact, together with colorectal cancer, these four cancer types account for 20 percent of all cancer-related deaths.
“The goal of the study to begin this fall is to show that version 2.0 of the vaccine is even better and that it may benefit a much bigger group of the overall cancer patient population,” says Dr. Snook.
The Latest on: Colorectal cancer vaccine
via Google News
The Latest on: Colorectal cancer vaccine
- Pfizer buys cancer treatment innovator Array BioPharma for $11 billion on June 18, 2019 at 4:44 am
In May, Pfizer opened a new $236 million research facility in Chesterfield that the company says will expand on its development of new medicines and vaccines ... of skin cancer. The company is also ... […]
- Mid-Afternoon Market Update: Crude Oil Down 1.5%; C&J Energy Services Shares Spike Higher on June 17, 2019 at 11:52 am
In the U.S., colorectal cancer is the third most common type of cancer in men ... The offer price represents a premium of 61% to Sotheby's closing price on Friday. VBI Vaccines Inc. (NASDAQ: VBIV) ... […]
- Mid-Morning Market Update: Markets Open Higher; Pfizer To Acquire Array BioPharma For $48/Share on June 17, 2019 at 7:16 am
In the U.S., colorectal cancer is the third most common type of cancer in men ... Equities Trading DOWN VBI Vaccines Inc. (NASDAQ: VBIV) shares tumbled 54% to $0.8692 after the company reported ... […]
- Anal Cancer: Why We Need to Talk More About This Deadly Disease on June 12, 2019 at 5:16 pm
Patients with anal cancer often will tell others they have bowel or colon cancer, which is perceived as more acceptable ... But in the meantime, there’s a preemptive strike available — a vaccine that ... […]
- What is Colon Cancer and how to treat it before it's too late? on June 11, 2019 at 5:27 pm
... now being developed is called a Personalized Neoantigen Vaccine or Personalized Cancer Vaccine. It is called a vaccine, but it doesn’t prevent colon cancer, it aims to cure patients even when the ... […]
- Chi-Huey Wong Examines Progress in the Development of Globo-H Cancer Vaccine on June 10, 2019 at 6:28 pm
Of these cases, the most commonly occurring cancers are those which infect the lungs, breasts, colon, stomach ... of the first carbohydrate-based cancer vaccines, specifically targeting breast ... […]
- The HPV Vaccine Is A Cancer Vaccine, Not A Sex Vaccine on June 7, 2019 at 9:07 pm
The actress wanted to share her story, not only to raise awareness of this rare cancer, which may go undetected well after the cancer develops, but also to bring the importance of the human ... […]
- Taipei hospital completes technology transfer for cancer drug on June 6, 2019 at 3:25 am
In testing on animals, the vaccine has been proven to be effective in curbing the growth of melanoma cells, liver cancer, colorectal carcinoma and cholangiocarcinoma, according to Lan. So far ... […]
- Marcia Cross wants to destigmatize anal cancer, says hers was linked to husband's battle on June 5, 2019 at 10:18 pm
Marcia Cross credits her annual rectal exam with saving her life ... Desperate Housewives' star wants to 'put a dent in the stigma around anal cancer' The science: HPV vaccine prevents anal cancer, ... […]
- Marcia Cross Learned Her Anal Cancer Likely Caused by Same HPV Strain as Husband’s Throat Cancer on June 5, 2019 at 9:10 am
With early immunization, kids can start receiving the HPV vaccine at age 9 ... will hopefully be less embarrassed about the disease and get a rectal exam, which is how she learned of her cancer. “I ... […]
via Bing News